IL-6 signaling drives self-renewal and alternative activation of adipose tissue macrophages

Front Immunol. 2024 Feb 28:15:1201439. doi: 10.3389/fimmu.2024.1201439. eCollection 2024.

Abstract

Introduction: Obesity is associated with chronic low-grade inflammation of adipose tissue (AT) and an increase of AT macrophages (ATMs) that is linked to the onset of type 2 diabetes. We have recently shown that neutralization of interleukin (IL)-6 in obese AT organ cultures inhibits proliferation of ATMs, which occurs preferentially in alternatively activated macrophage phenotype.

Methods: In this study, we investigated AT biology and the metabolic phenotype of mice with myeloid cell-specific IL-6Rα deficiency (Il6ra Δmyel) after normal chow and 20 weeks of high-fat diet focusing on AT inflammation, ATM polarization and proliferation. Using organotypical AT culture and bone marrow derived macrophages (BMDMs) of IL-4Rα knockout mice (Il4ra -/-) we studied IL-6 signaling.

Results: Obese Il6ra Δmyel mice exhibited no differences in insulin sensitivity or histological markers of AT inflammation. Notably, we found a reduction of ATMs expressing the mannose receptor 1 (CD206), as well as a decrease of the proliferation marker Ki67 in ATMs of Il6ra Δmyel mice. Importantly, organotypical AT culture and BMDM data of Il4ra -/- mice revealed that IL-6 mediates a shift towards the M2 phenotype independent from the IL-6/IL-4Rα axis.

Discussion: Our results demonstrate IL-4Rα-independent anti-inflammatory effects of IL-6 on macrophages and the ability of IL-6 to maintain proliferation rates in obese AT.

Keywords: IL-6; adipose tissue inflammation; alternative activation; diabetes; macrophages; mannose receptor; obesity; self-renewal.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipose Tissue / metabolism
  • Animals
  • Diabetes Mellitus, Type 2* / metabolism
  • Inflammation / metabolism
  • Interleukin-6* / metabolism
  • Macrophages / metabolism
  • Mice
  • Mice, Knockout
  • Obesity / metabolism

Substances

  • Interleukin-6

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – project number 209933838 – SFB 1052 (project B09) and supported by a student fellowship of the IFB Adiposity Diseases to JA (01EO1501). FW received funding from SFB 1454 P09.